Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Non Operating Income (2018 - 2025)

Historic Non Operating Income for Northwest Biotherapeutics (NWBO) over the last 10 years, with Q3 2025 value amounting to -$12.5 million.

  • Northwest Biotherapeutics' Non Operating Income fell 17354.03% to -$12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.9 million, marking a year-over-year decrease of 28965.68%. This contributed to the annual value of -$17.3 million for FY2024, which is 14354.82% down from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Non Operating Income of -$12.5 million as of Q3 2025, which was down 17354.03% from -$599000.0 recorded in Q2 2025.
  • Northwest Biotherapeutics' Non Operating Income's 5-year high stood at $144.0 million during Q4 2021, with a 5-year trough of -$17.2 million in Q3 2022.
  • Its 5-year average for Non Operating Income is $8.1 million, with a median of -$1.9 million in 2022.
  • As far as peak fluctuations go, Northwest Biotherapeutics' Non Operating Income soared by 21991.7% in 2023, and later tumbled by 93467.81% in 2024.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Non Operating Income stood at $144.0 million in 2021, then plummeted by 107.03% to -$10.1 million in 2022, then soared by 111.51% to $1.2 million in 2023, then plummeted by 934.68% to -$9.7 million in 2024, then decreased by 28.64% to -$12.5 million in 2025.
  • Its last three reported values are -$12.5 million in Q3 2025, -$599000.0 for Q2 2025, and -$2.0 million during Q1 2025.